Context Therapeutics (CNTX)
1.75
-0.28 (13.79%)
Upcoming Events
Latest Headlines
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
May 27, 2026 7:30 AM - StreetInsider
Form 8-K Context Therapeutics For: May 14
May 18, 2026 6:47 AM - SEC Filing
Context Therapeutics amends BioAtla license deal for CT-202 drug
May 18, 2026 6:45 AM - StreetInsider
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026 6:45 AM - Globe NewsWire
Form SCHEDULE 13G/A Context Therapeutics Filed by: GREAT POINT PARTNERS LLC
May 15, 2026 8:55 AM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Blue Owl Capital Holdings LP
May 14, 2026 4:21 PM - SEC Filing
Form SCHEDULE 13G Context Therapeutics Filed by: Octagon Capital Advisors LP
May 14, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Avidity Partners Management LP
May 12, 2026 3:08 PM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Soleus Capital Master Fund, L.P.
May 8, 2026 5:01 PM - SEC Filing
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
May 6, 2026 4:18 PM - Globe NewsWire
Form 10-Q Context Therapeutics For: Mar 31
May 6, 2026 4:11 PM - SEC Filing
Form 8-K Context Therapeutics For: Apr 30
May 1, 2026 4:08 PM - SEC Filing
Form ARS Context Therapeutics For: Dec 31
April 28, 2026 4:30 PM - SEC Filing
Form DEFA14A Context Therapeutics
April 28, 2026 4:17 PM - SEC Filing
Form DEF 14A Context Therapeutics For: Apr 28
April 28, 2026 4:13 PM - SEC Filing
Form PRE 14A Context Therapeutics For: Jun 24
April 17, 2026 4:29 PM - SEC Filing
Neogen appoints Jennifer Evans Stacey as chief legal officer
April 8, 2026 8:00 AM - StreetInsider
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
April 8, 2026 8:00 AM - BizWire
Jones Trading Assumes Context Therapeutics (CNTX) at Buy
April 6, 2026 4:16 PM - StreetInsider
Form 8-K Context Therapeutics For: Apr 02
April 2, 2026 7:41 AM - SEC Filing
Context Therapeutics receives FDA fast track status for ovarian cancer drug
April 2, 2026 7:30 AM - StreetInsider
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
April 2, 2026 7:30 AM - StreetInsider
Context Therapeutics (CNTX) Reiterated at Market Outperform by Citizens on FY25 Result
March 25, 2026 5:24 AM - StreetInsider
Context Therapeutics (CNTX) PT Raised to $7 at Piper Sandler
March 24, 2026 8:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Context Therapeutics (CNTX)
March 24, 2026 6:39 AM - StreetInsider
Form S-8 Context Therapeutics
March 23, 2026 5:09 PM - SEC Filing
Form 8-K Context Therapeutics For: Mar 23
March 23, 2026 4:22 PM - SEC Filing
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
March 23, 2026 4:17 PM - StreetInsider
Form 10-K Context Therapeutics For: Dec 31
March 23, 2026 4:10 PM - SEC Filing
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 19, 2026 7:30 AM - StreetInsider
Form 8-K Context Therapeutics For: Mar 11
March 13, 2026 4:09 PM - SEC Filing
Full Article List
